ARTEMIs CDSS will assist MASLD management, throughout the patient journey. The MASLD spectrum goes from an initial silent disease where fat accumulation can be reverse by adopting healthier life habits, into a pathological condition which can deteriorate into lethal decompensated cirrhosis, HCC or Acute or Chronic Liver Failure.
One main disease path in the progression of MASLD is the development of fibrosis, progressing towards cirrhosis, and in about 5 10%/year from there to hepatocellular carcinoma. More than 60% of patients with MASLD have some degree of fibrosis, although progression is slow. The first step in managing the disease progression is acting on the cause (e.g. healthier life habits, weight reduction), and the secondary approach is to address the fibrogenesis.
